Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 5;6(1):1-7.
doi: 10.15586/jkcvhl.2019.114. eCollection 2019.

Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?

Alex Renner  1 , Suraj Samtani  2 , Arnaldo Marín  3 , Mauricio Burotto  4
Affiliations
Review

Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?

Alex Renner et al. J Kidney Cancer VHL. .

Abstract

Cytoreductive nephrectomy has been an integral part of management in metastatic renal cell carcinoma for patients with good performance status, based on the benefit shown by prospective trials in the interferon era and retrospective trials in the targeted therapies era. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA), the first prospective phase III trial comparing a targeted agent alone (sunitinib) versus nephrectomy plus sunitinib, has been recently published, showing non-inferiority for the nephrectomy-sparing arm. In this article, we discuss the impact of nephrectomy including its immune-mediated effects, surgical morbidity and mortality, and the clinical data supporting the indications of nephrectomy in order to analyze the CARMENA trial in context, with the aim to identify optimal strategies for different patient populations in the metastatic setting.

Keywords: cytoreductive nephrectomy; immunotherapy; metastatic renal cell carcinoma; sunitinib; surgical outlook.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.

References

    1. Stewart B, Wild C. International Agency for Research on Cancer, WHO. World cancer report 2014 [Internet]. [cited 2019 Jan 20]. Available from: http://www.thehealthwell.info/node/725845
    1. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. . SEER cancer statistics review, 1975–2015. National Cancer Institute [Internet] [cited 2019 Jan 20]. Available from: https://seer.cancer.gov/csr/1975_2015/
    1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007. January 11;356(2):115–24. 10.1056/NEJMoa065044 - DOI - PubMed
    1. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. . Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001. December 6;345(23):1655–9. 10.1056/NEJMoa003013 - DOI - PubMed
    1. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group . Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 2001. September 22;358(9286):966–70. 10.1016/S0140-6736(01)06103-7 - DOI - PubMed

LinkOut - more resources